Variables | Progression-free survival | Overall survival | ||||
---|---|---|---|---|---|---|
HR | 95Â % CI | P value | HR | 95Â % CI | P value | |
Best objective response on target lesions | ||||||
 CR/PR | 1 |  |  | 1 |  |  |
 SD | 1.67 | 0.61–4.60 | 0.23 | 4.51 | 0.95–21.4 | 0.06 |
 PD | 1.88 | 0.52–6.84 | 0.09 | 7.93 | 1.36–47.8 | 0.02 |
 NE | 3.56 | 1.00–12.9 | 0.05 | 4.88 | 1.02–23.2 | 0.04 |
Heng risk group | ||||||
 Favorable | 1 |  |  | 1 |  |  |
 Intermediate | 2.70 | 0.97–7.56 | 0.06 | 2.69 | 0.61–11.9 | 0.19 |
 Poor | 14.50 | 4.42–48.0 | 0.001 | 10.1 | 2.03–50.6 | 0.01 |
Serum CRP level (mg/dL) | ||||||
 ≤0.3 | 1 |  |  | 1 |  |  |
 0.3< | 1.68 | 0.72–3.96 | 0.23 | 1.50 | 0.58–3.91 | 0.40 |
Serum sodium level (mmol/L) | ||||||
 ≥135 | NA | 1 |  |  | ||
 135> | 1.65 | 0.63–4.30 | 0.31 | |||
Hypertension related to sunitinib | ||||||
 Yes | 1 |  |  | NA | ||
 No | 3.14 | 1.55–6.36 | 0.002 |